
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/440491/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oral Delivery of Encapsulated All-Trans Retinoic Acid Ameliorates Disease in Rodent Models of Colitis. Inflammatory Bowel Diseases, 2022, 28, 455-465.	1.9	4
2	Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs. Genes, 2022, 13, 703.	2.4	3
3	Computational Analysis of Pathogenetic Pathways in Alzheimer's Disease and Prediction of Potential Therapeutic Drugs. Brain Sciences, 2022, 12, 827.	2.3	3
4	Macrophage Migration Inhibitory Factor (MIF) and Its Homologue D-Dopachrome Tautomerase (DDT) Inversely Correlate with Inflammation in Discoid Lupus Erythematosus. Molecules, 2021, 26, 184.	3.8	11
5	Potential Mucosal Irritation Discrimination of Surface Disinfectants Employed against SARS-CoV-2 by Limacus flavus Slug Mucosal Irritation Assay. Biomedicines, 2021, 9, 424.	3.2	3
6	A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy. Genes, 2021, 12, 543.	2.4	5
7	Antimicrobial properties of <i>Lactobacillus</i> cellâ€free supernatants against multidrugâ€resistant urogenital pathogens. MicrobiologyOpen, 2021, 10, e1173.	3.0	46
8	Altered Expression of TSPAN32 during B Cell Activation and Systemic Lupus Erythematosus. Genes, 2021, 12, 931.	2.4	3
9	Transcriptomic Data Analysis Reveals a Down-Expression of Galectin-8 in Schizophrenia Hippocampus. Brain Sciences, 2021, 11, 973.	2.3	2
10	Therapeutic Potential of Alpha-Lipoic Acid in Viral Infections, including COVID-19. Antioxidants, 2021, 10, 1294.	5.1	19
11	A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110501.	2.1	26
12	Novel 3,3-disubstituted oxindole derivatives. Synthesis and evaluation of the anti-proliferative activity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126845.	2.2	17
13	Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis. Molecules, 2020, 25, 4310.	3.8	6
14	Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. International Journal of Molecular Sciences, 2020, 21, 8803.	4.1	7
15	Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?. Pharmaceuticals, 2020, 13, 411.	3.8	21
16	Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease. Brain Sciences, 2020, 10, 166.	2.3	12
17	Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?. Molecules, 2020, 25, 1194.	3.8	25
18	Impaired Expression of Tetraspanin 32 (TSPAN32) in Memory T Cells of Patients with Multiple Sclerosis. Brain Sciences, 2020, 10, 52.	2.3	13

#	Article	IF	CITATIONS
19	The Role of Macrophage Migration Inhibitory Factor in Alzheimer′s Disease: Conventionally Pathogenetic or Unconventionally Protective?. Molecules, 2020, 25, 291.	3.8	31
20	The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 3023.	4.1	15
21	Transcriptomic Analysis Reveals Abnormal Expression of Prion Disease Gene Pathway in Brains from Patients with Autism Spectrum Disorders. Brain Sciences, 2020, 10, 200.	2.3	2
22	Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players. Oncology Letters, 2020, 20, 332.	1.8	8
23	Transcriptomic analysis reveals moderate modulation of macrophage migration inhibitory factor superfamily genes in alcohol use disorders. Experimental and Therapeutic Medicine, 2020, 19, 1755-1762.	1.8	4
24	Effects of GIT-27NO, a NO-donating compound, on hepatic ischemia/reperfusion injury. International Journal of Immunopathology and Pharmacology, 2019, 33, 205873841986273.	2.1	3
25	Upregulated Expression of Macrophage Migration Inhibitory Factor, Its Analogue D-Dopachrome Tautomerase, and the CD44 Receptor in Peripheral CD4 T Cells from Clinically Isolated Syndrome Patients with Rapid Conversion to Clinical Defined Multiple Sclerosis. Medicina (Lithuania), 2019, 55, 667.	2.0	26
26	Overexpression of Macrophage Migration Inhibitory Factor and Its Homologue D-Dopachrome Tautomerase as Negative Prognostic Factor in Neuroblastoma. Brain Sciences, 2019, 9, 284.	2.3	26
27	Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling. Brain Sciences, 2019, 9, 221.	2.3	22
28	Modulation of Tetraspanin 32 (TSPAN32) Expression in T Cell-Mediated Immune Responses and in Multiple Sclerosis. International Journal of Molecular Sciences, 2019, 20, 4323.	4.1	23
29	Identification of CD4+ T cell biomarkers for predicting the response of patients with relapsing‑remitting multiple sclerosis to natalizumab treatment. Molecular Medicine Reports, 2019, 20, 678-684.	2.4	27
30	Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF. Journal of Neuroimmunology, 2019, 332, 224-232.	2.3	29
31	Senescence as a main mechanism of Ritonavir and Ritonavirâ€NO action against melanoma. Molecular Carcinogenesis, 2019, 58, 1362-1375.	2.7	18
32	KCNMA1 Expression is Downregulated in Colorectal Cancer via Epigenetic Mechanisms. Cancers, 2019, 11, 245.	3.7	23
33	Effects of Treatment with the Hypomethylating Agent 5-aza-2′-deoxycytidine in Murine Type II Collagen-Induced Arthritis. Pharmaceuticals, 2019, 12, 174.	3.8	17
34	Transcriptomic Analysis Reveals Involvement of the Macrophage Migration Inhibitory Factor Gene Network in Duchenne Muscular Dystrophy. Genes, 2019, 10, 939.	2.4	16
35	Effects of a newÂcombination of plant extracts plusd-mannose for the management of uncomplicated recurrent urinary tract infections. Journal of Chemotherapy, 2018, 30, 107-114.	1.5	41
36	Involvement of the Nrf2/HOâ€1/CO axis and therapeutic intervention with the COâ€releasing molecule CORMâ€A1, in a murine model of autoimmune hepatitis. Journal of Cellular Physiology, 2018, 233, 4156-4165.	4.1	47

#	Article	IF	CITATIONS
37	Immunomodulatory Effects of Bifidobacterium longum W11 Produced Exopolysaccharide on Cytokine Production. Current Pharmaceutical Biotechnology, 2018, 18, 883-889.	1.6	21
38	Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. Oncotarget, 2018, 9, 8263-8277.	1.8	75
39	Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences. Journal of Neuroimmunology, 2018, 322, 46-56.	2.3	69
40	Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis. Journal of Neuroimmunology, 2018, 321, 41-48.	2.3	13
41	Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget, 2018, 9, 17951-17970.	1.8	60
42	Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone. Experimental and Therapeutic Medicine, 2017, 14, 2439-2444.	1.8	15
43	Standardized bovine colostrum derivative impedes development of type 1 diabetes in rodents. Immunobiology, 2017, 222, 272-279.	1.9	6
44	Expression of DNA methylation genes in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2016, 290, 66-69.	2.3	17
45	Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease. Angiology, 2016, 67, 870-874.	1.8	32
46	Emerging therapeutic targets for the treatment of hepatic fibrosis. Drug Discovery Today, 2016, 21, 369-375.	6.4	71
47	Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 306-315.	2.5	19
48	Oral Delivery of Particulate Transforming Growth Factor Beta 1 and All-Trans Retinoic Acid Reduces Gut Inflammation in Murine Models of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2015, 9, 647-658.	1.3	24
49	Identification of novel targets for the diagnosis and treatment of liver fibrosis. International Journal of Molecular Medicine, 2015, 36, 747-752.	4.0	46
50	Carbon monoxide-releasing molecule-A1 (CORM-A1) improves clinical signs of experimental autoimmune uveoretinitis (EAU) in rats. Clinical Immunology, 2015, 157, 198-204.	3.2	33
51	Calcium butyrate: Anti-inflammatory effect on experimental colitis in rats and antitumor properties. Biomedical Reports, 2014, 2, 559-563.	2.0	15
52	Saquinavirâ€ <scp>NO</scp> Inhibits <scp>IL</scp> â€6 Production in Macrophages. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 499-506.	2.5	3
53	Acceleration of SLE-like syndrome development in NZBxNZW F1 mice by beta-glucan. Lupus, 2014, 23, 407-411.	1.6	9
54	Hypomethylating Agent 5â€Azaâ€2â€2â€deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models. Journal of Cellular Physiology, 2014, 229, 1918-1925.	4.1	45

#	Article	IF	CITATIONS
55	Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects. Diabetologia, 2014, 57, 980-990.	6.3	66
56	<scp>VGX</scp> â€1027 modulates genes involved in lipopolysaccharideâ€induced <scp>T</scp> ollâ€ike receptor 4 activation and in a murine model of systemic lupus erythematosus. Immunology, 2014, 142, 594-602.	4.4	37
57	Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Antiâ€Tumour Potency on Prostate Cancer Cells. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 63-69.	2.5	14
58	Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. Journal of Neuroimmunology, 2013, 261, 82-86.	2.3	45
59	Association of chitotriosidase genotype with the development of nonâ€alcoholic fatty liver disease. Hepatology Research, 2013, 43, 267-275.	3.4	21
60	Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2013, 262, 72-78.	2.3	7
61	Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2013, 259, 55-65.	2.3	9
62	lsoproterenol modulates matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor-2 (TIMP-2) in rat parotid gland. Archives of Oral Biology, 2013, 58, 370-376.	1.8	2
63	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST ĆELIJA NESITNOĆELIJSKOG KARCINOMA PLUĆA RAZLIČITE OSETUIVOSTI NA DOKSORUBICIN. Journal of Me Biochemistry. 2013. 32. 406-416.	dical	2
64	Neopterin: A potential marker in chronic peripheral arterial disease. Molecular Medicine Reports, 2013, 7, 1855-1858.	2.4	13
65	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle, 2012, 11, 1174-1182.	2.6	14
66	Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells. Molecular Pharmacology, 2012, 82, 700-710.	2.3	28
67	Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. Oncology Reports, 2012, 28, 682-688.	2.6	18
68	Therapeutic potential of carbon monoxide in multiple sclerosis. Clinical and Experimental Immunology, 2012, 167, 179-187.	2.6	55
69	The immunobiology of apotransferrin in type 1 diabetes. Clinical and Experimental Immunology, 2012, 169, 244-252.	2.6	6
70	Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. Cytokine, 2011, 55, 165-167.	3.2	41
71	Novel components of the human metabolome: The identification, characterization and anti-inflammatory activity of two 5-androstene tetrols. Steroids, 2011, 76, 145-155.	1.8	15
72	Influence of lactoferrin in preventing preterm delivery: A pilot study. Molecular Medicine Reports, 2011, 5, 162-6.	2.4	23

#	Article	IF	CITATIONS
73	Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients. International Journal of Molecular Medicine, 2011, 28, 437-42.	4.0	4
74	Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. Clinical and Experimental Immunology, 2011, 163, 368-374.	2.6	65
75	HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse. European Journal of Pharmacology, 2011, 658, 257-262.	3.5	9
76	Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. Journal of Cellular Physiology, 2011, 226, 1803-1812.	4.1	30
77	Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis. International Journal of Molecular Medicine, 2010, 25, 625-33.	4.0	11
78	Expression and localization of prominin-1 in isoproterenol-treated rat parotid gland. International Journal of Molecular Medicine, 2010, 26, 505-10.	4.0	1
79	HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression. Journal of Inflammation, 2010, 7, 52.	3.4	11
80	Specific and Strain-Independent Effects of Dexamethasone in the Prevention and Treatment of Experimental Autoimmune Encephalomyelitis in Rodents. Scandinavian Journal of Immunology, 2010, 72, 396-407.	2.7	26
81	5-Androstenediol Ameliorates Pleurisy, Septic Shock, and Experimental Autoimmune Encephalomyelitis in Mice. Autoimmune Diseases, 2010, 2010, 1-8.	0.6	11
82	HE3286: A Novel Synthetic Steroid as an Oral Treatment for Autoimmune Disease. Annals of the New York Academy of Sciences, 2009, 1173, 781-790.	3.8	18
83	The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. Journal of Neuroimmunology, 2009, 207, 101-106.	2.3	72
84	T.84. Efficacy of a Novel Synthetic Steroid, TRIOLEXâ,,¢ (17α-ethynyl-5-androsten-3β, 7β, 17β-triol), in Spontaneous Autoimmune Diabetes in the Non-Obese Diabetic (NOD) Mouse. Clinical Immunology, 2009, 131, S75.	3.2	0
85	The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. European Journal of Pharmacology, 2009, 615, 228-233.	3.5	15
86	16α-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. Clinical and Experimental Immunology, 2009, 158, 308-316.	2.6	7
87	Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clinical and Experimental Immunology, 2009, 155, 28-34.	2.6	53
88	The antitumor properties of a nontoxic, nitric oxide–modified version of saquinavir are independent of Akt. Molecular Cancer Therapeutics, 2009, 8, 1169-1178.	4.1	38
89	Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. Journal of Autoimmunity, 2009, 33, 135-140.	6.5	70
90	Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clinical and Experimental Immunology, 2009, 159, 159-168.	2.6	26

#	Article	IF	CITATIONS
91	Efficacy of Intracolonic Administration of Low-Molecular-Weight Heparin CB-01-05, Compared to Other Low-Molecular-Weight Heparins and Unfractionated Heparin, in Experimentally Induced Colitis in Rat. Digestive Diseases and Sciences, 2008, 53, 3170-3175.	2.3	23
92	Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. Journal of Cellular Physiology, 2008, 215, 665-675.	4.1	76
93	Effects of the immunomodulator, VGXâ€1027, in endotoxinâ€induced uveitis in Lewis rats. British Journal of Pharmacology, 2008, 155, 722-730.	5.4	8
94	In vitro inhibition of enterobacteria-reactive CD4+CD25â^' T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. European Journal of Pharmacology, 2008, 586, 313-321.	3.5	14
95	Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barrè syndrome. Journal of Neuroimmunology, 2008, 196, 107-115.	2.3	8
96	Anticancer properties of the novel nitric oxide-donating compound ( <i>S,R</i> )-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide <i>in vitro</i> and <i>in vivo</i> . Molecular Cancer Therapeutics, 2008, 7, 510-520.	4.1	68
97	A Potent Immunomodulatory Compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxasole Acetic Acid, Prevents Spontaneous and Accelerated Forms of Autoimmune Diabetes in NOD Mice and Inhibits the Immunoinflammatory Diabetes Induced by Multiple Low Doses of Streptozotocin in CBA/H Mice. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1038-1049.	2.5	32
98	In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clinical Immunology, 2007, 123, 311-323.	3.2	61
99	Detection of <i>BRAF</i> gene mutation in primary choroidal melanoma tissue. Cancer Biology and Therapy, 2006, 5, 225-227.	3.4	34
100	Immunomodulatory Properties of Cefaclor:In VivoEffect on Cytokine Release and Lymphoproliferative Response in Rats. Journal of Chemotherapy, 2006, 18, 641-647.	1.5	9
101	Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncology Reports, 2006, 15, 1305-8.	2.6	16
102	Anti-inflammatory and Immune Regulatory Properties of 5-Androsten-3β, 17β-Diol (HE2100), and Synthetic Analogue HE3204: Implications for Treatment of Autoimmune Diseases. Annals of the New York Academy of Sciences, 2005, 1051, 730-742.	3.8	14
103	Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain–Barré syndrome and experimental allergic neuritis. Journal of Neuroimmunology, 2005, 168, 168-174.	2.3	63
104	Exacerbation of protracted-relapsing experimental allergic encephalomyelitis in DA rats by gluten-free diet. Apmis, 2004, 112, 651-5.	2.0	4
105	Exacerbation of protracted-relapsing experimental allergic encephalomyelitis in DA rats by gluten-free diet. Apmis, 2004, 112, 651-5.	2.0	17
106	Protection against murine endotoxemia by treatment with Ruta Chalepensis L., a plant with anti-inflammatory properties. Journal of Ethnopharmacology, 2004, 90, 267-272.	4.1	55
107	Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. Clinical Immunology, 2003, 109, 266-271.	3.2	5
108	Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures. Journal of Neuroscience, 2002, 22, 5403-5411.	3.6	79

#	Article	IF	CITATIONS
109	Prevention and Treatment of Lethal Murine Endotoxemia by the Novel Immunomodulatory Agent MFP-14. Antimicrobial Agents and Chemotherapy, 2001, 45, 1591-1594.	3.2	1